Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

Conditions:   Choroideremia;   X-Linked Retinitis Pigmentosa
Interventions:   Genetic: BIIB111;   Genetic: BIIB112
Sponsor:   NightstaRx Ltd, a Biogen Company
Enrolling by invitation
This is a companion discussion topic for the original entry at https://clinicaltrials.gov/ct2/show/NCT03584165?recrs=abf&cond=Choroideremia&lupd_s=04%2F14%2F2022&lupd_d=14